These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 15225107)
1. Angiotensin-receptor blockade in renal disease: the hard issues. Sica DA Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):469-71. PubMed ID: 15225107 [No Abstract] [Full Text] [Related]
2. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be? Hollenberg NK; Epstein M Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325 [No Abstract] [Full Text] [Related]
4. FPIN's clinical inquiries. Angiotensin blockade in patients with diabetic nephropathy. Jimenez J; Safranek S; Viera AJ Am Fam Physician; 2007 Aug; 76(3):423-4. PubMed ID: 17708144 [No Abstract] [Full Text] [Related]
5. [ACE inhibitors and AT-II antagonists--do they protect against renal disease?]. Rossing P; Parving HH Ugeskr Laeger; 2006 Apr; 168(15):1564; author reply1564-5. PubMed ID: 16640990 [No Abstract] [Full Text] [Related]
6. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II). Jacobsen PK J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484 [TBL] [Abstract][Full Text] [Related]
7. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney. Bilous R Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685 [No Abstract] [Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Hughes DB; Britton ML Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022 [TBL] [Abstract][Full Text] [Related]
10. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients. Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912 [TBL] [Abstract][Full Text] [Related]
11. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Vogt L; Kocks MJ; Laverman GD; Navis G Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515 [TBL] [Abstract][Full Text] [Related]
12. Treating diabetic nephropathy: unfinished success is not failure. Lewis J Clin J Am Soc Nephrol; 2007 May; 2(3):407-9. PubMed ID: 17699442 [No Abstract] [Full Text] [Related]
14. [Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2]. Zidek W MMW Fortschr Med; 2004 Oct; 146(42):51-2. PubMed ID: 15536706 [No Abstract] [Full Text] [Related]
15. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Abuissa H; O'Keefe J Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810 [TBL] [Abstract][Full Text] [Related]
16. [RAS blockade in diabetic nephropathy. "Early intervention can dramatically decrease loss of function]. Ritz E MMW Fortschr Med; 2004 Sep; 146(38):12. PubMed ID: 15532423 [No Abstract] [Full Text] [Related]
17. ARBs vs ACE inhibitors for preventing diabetic nephropathy. Greenwood V J Fam Pract; 2005 May; 54(5):453; discussion 453-4. PubMed ID: 15865904 [No Abstract] [Full Text] [Related]
18. ACE inhibitors as a shield against diabetic nephropathy. Materson BJ Arch Intern Med; 1996 Feb; 156(3):239-40. PubMed ID: 8572832 [No Abstract] [Full Text] [Related]
19. ACE inhibitors vs. ARBs for patients with diabetic kidney disease. Bailey J Am Fam Physician; 2007 Jul; 76(1):68-9. PubMed ID: 17668841 [No Abstract] [Full Text] [Related]
20. The road to renal failure: an overview of diabetic nephropathy. McCrary EB Adv Nurse Pract; 2008 Jul; 16(7):61-3. PubMed ID: 19181161 [No Abstract] [Full Text] [Related] [Next] [New Search]